136 related articles for article (PubMed ID: 19167858)
21. Matrix metalloproteinase expression in the recurrence of superficial low grade bladder transitional cell carcinoma.
Choi YD; Cho NH; Ahn HS; Cho KS; Cho SY; Yang WJ
J Urol; 2007 Mar; 177(3):1174-8. PubMed ID: 17296440
[TBL] [Abstract][Full Text] [Related]
22. Correlation of REG1A, Claudin 7 and Ki67 expressions with tumor recurrence and prognostic factors in superficial urothelial urinary bladder carcinomas.
Yamuç E; Barışık NÖ; Şensu S; Tarhan F; Barışık CC
Indian J Pathol Microbiol; 2022; 65(2):355-361. PubMed ID: 35435371
[TBL] [Abstract][Full Text] [Related]
23. Ta T1 low and intermediate transitional cell carcinoma of the bladder: recurrence rates and the timing of check cystoscopies within the first year.
Guney S; Guney N; Canogullari Z; Ergenekon E
Urol Int; 2008; 80(2):124-8. PubMed ID: 18362479
[TBL] [Abstract][Full Text] [Related]
24. Peroxisome proliferator-activated receptor gamma expression in urothelial carcinomas of the bladder: association with differentiation, proliferation and clinical outcome.
Mylona E; Giannopoulou I; Diamantopoulou K; Bakarakos P; Nomikos A; Zervas A; Nakopoulou L
Eur J Surg Oncol; 2009 Feb; 35(2):197-201. PubMed ID: 18513919
[TBL] [Abstract][Full Text] [Related]
25. Gene expression analysis for the prediction of recurrence in patients with primary Ta urothelial cell carcinoma.
Schultz IJ; Wester K; Straatman H; Kiemeney LA; Babjuk M; Mares J; Willems JL; Swinkels DW; Witjes JA; Malmström PU; de Kok JB
Eur Urol; 2007 Feb; 51(2):416-22; discussion 422-3. PubMed ID: 16920253
[TBL] [Abstract][Full Text] [Related]
26. Loss of APKC expression independently predicts tumor recurrence in superficial bladder cancers.
Namdarian B; Wong E; Galea R; Pedersen J; Chin X; Speirs R; Humbert PO; Costello AJ; Corcoran NM; Hovens CM
Urol Oncol; 2013 Jul; 31(5):649-55. PubMed ID: 21549621
[TBL] [Abstract][Full Text] [Related]
27. Expression of survivin and its spliced variants in bladder tumors as a potential prognostic marker.
Nouraee N; Mowla SJ; Ozhand A; Parvin M; Ziaee SA; Hatefi N
Urol J; 2009; 6(2):101-8. PubMed ID: 19472128
[TBL] [Abstract][Full Text] [Related]
28. BCL-2, TP53 and BAX protein expression in superficial urothelial bladder carcinoma.
Gonzalez-Campora R; Davalos-Casanova G; Beato-Moreno A; Garcia-Escudero A; Pareja Megia MJ; Montironi R; Lopez-Beltran A
Cancer Lett; 2007 Jun; 250(2):292-9. PubMed ID: 17126995
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical expression and prognostic significance of FAS and GLUT1 in bladder carcinoma.
Visca P; Sebastiani V; Pizer ES; Botti C; De Carli P; Filippi S; Monaco S; Alo PL
Anticancer Res; 2003; 23(1A):335-9. PubMed ID: 12680233
[TBL] [Abstract][Full Text] [Related]
30. HER2 status in primary stage T1 urothelial cell carcinoma of the urinary bladder.
Olsson H; Fyhr IM; Hultman P; Jahnson S
Scand J Urol Nephrol; 2012 Apr; 46(2):102-7. PubMed ID: 22150625
[TBL] [Abstract][Full Text] [Related]
31. Differences in tumor characteristics and prognosis in newly diagnosed Ta, T1 urothelial carcinoma of bladder according to patient age.
Cho KS; Hwang TK; Kim BW; Yoon DK; Chang SG; Kim SJ; Park JY; Cheon J; Sung GT; Hong SJ;
Urology; 2009 Apr; 73(4):828-32, 832.e1. PubMed ID: 19195693
[TBL] [Abstract][Full Text] [Related]
32. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17.
Simonetti S; Russo R; Ciancia G; Altieri V; De Rosa G; Insabato L
Int J Surg Pathol; 2009 Jun; 17(3):198-205. PubMed ID: 19443884
[TBL] [Abstract][Full Text] [Related]
33. Predictive value of N-acetylglucosaminyltransferase-V for superficial bladder cancer recurrence.
Takahashi T; Hagisawa S; Yoshikawa K; Tezuka F; Kaku M; Ohyama C
J Urol; 2006 Jan; 175(1):90-3; discussion 93. PubMed ID: 16406879
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of microsatellite instability determined by immunohistochemical staining of hMSH2 and hMSH6 in urothelial carcinoma of the bladder.
Mylona E; Zarogiannos A; Nomikos A; Giannopoulou I; Nikolaou I; Zervas A; Nakopoulou L
APMIS; 2008 Jan; 116(1):59-65. PubMed ID: 18254781
[TBL] [Abstract][Full Text] [Related]
35. Grade and stage at presentation do not predict mortality in patients with bladder cancer who survive their disease.
Messing EM; Madeb R; Feng C; Stephenson L; Gilchrist KW; Young T; Gee J
J Clin Oncol; 2009 May; 27(15):2443-9. PubMed ID: 19332735
[TBL] [Abstract][Full Text] [Related]
36. Prognostic relevance of prothymosin-alpha expression in human upper urinary tract transitional cell carcinoma.
Jou YC; Tung CL; Tsai YS; Shen CH; Syue-Yi C; Shiau AL; Tsai HT; Wu CL; Tzai TS
Urology; 2009 Oct; 74(4):951-7. PubMed ID: 19679339
[TBL] [Abstract][Full Text] [Related]
37. Cyclooxygenase-2 protein expression in relation to apoptotic potential and its prognostic significance in bladder urothelial carcinoma.
Diamantopoulou K; Lazaris A; Mylona E; Zervas A; Stravodimos K; Nikolaou I; Athanassiadou S; Nakopoulou L
Anticancer Res; 2005; 25(6C):4543-9. PubMed ID: 16334139
[TBL] [Abstract][Full Text] [Related]
38. Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and -7 and E-cadherin.
Miyata Y; Sagara Y; Kanda S; Hayashi T; Kanetake H
Hum Pathol; 2009 Apr; 40(4):496-504. PubMed ID: 19121849
[TBL] [Abstract][Full Text] [Related]
39. Enhanced expression of peroxiredoxin I and VI correlates with development, recurrence and progression of human bladder cancer.
Quan C; Cha EJ; Lee HL; Han KH; Lee KM; Kim WJ
J Urol; 2006 Apr; 175(4):1512-6. PubMed ID: 16516038
[TBL] [Abstract][Full Text] [Related]
40. The prognostic predictors of primary ureteral transitional cell carcinoma after radical nephroureterectomy.
Li WM; Li CC; Ke HL; Wu WJ; Huang CN; Huang CH
J Urol; 2009 Aug; 182(2):451-8; discussion 458. PubMed ID: 19524962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
